PDF(Pubmed)
Abstract：
UNASSIGNED: The glycoprotein fetuin-A has anti-inflammatory effects, increases insulin resistance and plays an important role in calcium metabolism. The aim of our study was to assess the predictive value of fetuin-A on atherosclerotic plaque progression in comparison to the established cardiovascular biomarker high sensitivity C-reactive protein (hsCRP).
UNASSIGNED: In this prospective, single center-, cohort study, we included 194 patients with at least one cardiovascular risk factor or established cardiovascular disease (CVD). Over a period of 4 years, each patient underwent 3D plaque volumetry of the carotid and femoral arteries on a yearly basis. To evaluate the predictive value of biomarkers in terms of plaque progression, the baseline values of fetuin-A and hsCRP were correlated with the plaque progression from baseline to the last follow up visit.
UNASSIGNED: 171 patients were included in the final analysis. Baseline fetuin-A levels showed a significant negative correlation with plaque progression (r = -0.244; p = 0.001). In contrast, baseline hsCRP levels showed no correlation with plaque progression (r = 0.096, p = 0.20). In the ROC-analysis, fetuin-A had a significantly better predictive value than hsCRP (fetuin-A AUC 0.67; p = 0.001 vs hsCRP AUC 0.49; p = 0.88) with an optimal cut-off value at 712 μg/ml. In patients with high fetuin A levels (>712 μg/ml), a significantly lower plaque progression was observed compared to the group with low fetuin-A levels <712 μg/ml (high fetuin-A 197 mm3 vs. low fetuin-A 279 mm3; p = 0.01).
UNASSIGNED: Higher fetuin-A levels appear to predict lower atherosclerotic plaque progression in patients with or at risk of cardiovascular disease.
UNASSIGNED: In this prospective, single center-, cohort study, we included 194 patients with at least one cardiovascular risk factor or established cardiovascular disease (CVD). Over a period of 4 years, each patient underwent 3D plaque volumetry of the carotid and femoral arteries on a yearly basis. To evaluate the predictive value of biomarkers in terms of plaque progression, the baseline values of fetuin-A and hsCRP were correlated with the plaque progression from baseline to the last follow up visit.
UNASSIGNED: 171 patients were included in the final analysis. Baseline fetuin-A levels showed a significant negative correlation with plaque progression (r = -0.244; p = 0.001). In contrast, baseline hsCRP levels showed no correlation with plaque progression (r = 0.096, p = 0.20). In the ROC-analysis, fetuin-A had a significantly better predictive value than hsCRP (fetuin-A AUC 0.67; p = 0.001 vs hsCRP AUC 0.49; p = 0.88) with an optimal cut-off value at 712 μg/ml. In patients with high fetuin A levels (>712 μg/ml), a significantly lower plaque progression was observed compared to the group with low fetuin-A levels <712 μg/ml (high fetuin-A 197 mm3 vs. low fetuin-A 279 mm3; p = 0.01).
UNASSIGNED: Higher fetuin-A levels appear to predict lower atherosclerotic plaque progression in patients with or at risk of cardiovascular disease.
摘要：
未经证实：糖蛋白胎球蛋白A具有抗炎作用，增加胰岛素抵抗，在钙代谢中起重要作用。本研究的目的是与已建立的心血管生物标志物高敏C反应蛋白（hsCRP）相比，评估胎球蛋白A对动脉粥样硬化斑块进展的预测价值。
未经批准：在此前瞻性中，单中心-，队列研究,我们纳入了194例至少有一种心血管危险因素或已确诊心血管疾病(CVD)的患者.在4年的时间里，每例患者每年接受颈动脉和股动脉的3D斑块容积测定.为了评估生物标志物在斑块进展方面的预测价值，胎球蛋白A和hsCRP的基线值与从基线到最后一次随访的斑块进展相关.
UNASSIGNED：171例患者纳入最终分析。基线胎球蛋白A水平与斑块进展呈显著负相关(r=-0.244;p=0.001)。相比之下,基线hsCRP水平与斑块进展无相关性(r=0.096,p=0.20).在ROC分析中，胎球蛋白A的预测价值明显优于hsCRP（胎球蛋白AAUC0.67;p=0.001vshsCRPAUC0.49;p=0.88），最佳临界值为712μg/ml。在高胎球蛋白A水平（>712μg/ml）的患者中，与低胎球蛋白-A水平<712μg/ml的组相比，观察到斑块进展显着降低（高胎球蛋白-A197mm3与低胎球蛋白-A279mm3；p=0.01）。
未经证实：在患有心血管疾病或有心血管疾病风险的患者中，较高的胎球蛋白-A水平似乎可预测较低的动脉粥样硬化斑块进展。
未经批准：在此前瞻性中，单中心-，队列研究,我们纳入了194例至少有一种心血管危险因素或已确诊心血管疾病(CVD)的患者.在4年的时间里，每例患者每年接受颈动脉和股动脉的3D斑块容积测定.为了评估生物标志物在斑块进展方面的预测价值，胎球蛋白A和hsCRP的基线值与从基线到最后一次随访的斑块进展相关.
UNASSIGNED：171例患者纳入最终分析。基线胎球蛋白A水平与斑块进展呈显著负相关(r=-0.244;p=0.001)。相比之下,基线hsCRP水平与斑块进展无相关性(r=0.096,p=0.20).在ROC分析中，胎球蛋白A的预测价值明显优于hsCRP（胎球蛋白AAUC0.67;p=0.001vshsCRPAUC0.49;p=0.88），最佳临界值为712μg/ml。在高胎球蛋白A水平（>712μg/ml）的患者中，与低胎球蛋白-A水平<712μg/ml的组相比，观察到斑块进展显着降低（高胎球蛋白-A197mm3与低胎球蛋白-A279mm3；p=0.01）。
未经证实：在患有心血管疾病或有心血管疾病风险的患者中，较高的胎球蛋白-A水平似乎可预测较低的动脉粥样硬化斑块进展。
